Skip to content
2000
Volume 5, Issue 3
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Cholesteryl ester transfer protein (CETP) facilitates the exchange of neutral lipids (such as cholesteryl esters and triglycerides) between anti-atherogenic HDL particles and pro-atherogenic VLDL and LDL particles in human plasma. Individuals possessing a genetic deficiency for CETP have higher HDL cholesterol and lower LDL cholesterol and may have a reduced risk for developing cardiovascular disease. Small molecule inhibitors of CETP are being developed that would appear to provide a beneficial change in lipoprotein profile. However, randomized clinical trials are ultimately required to determine whether CETP inhibition will afford a reduction in cardiovascular events.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026053544506
2005-04-01
2025-06-18
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026053544506
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test